Imaavy is a medicine to treat adults and adolescents aged 12 years and older with generalised myasthenia gravis, an autoimmune disease in which the immune system (the body’s natural defences) disrupts communication between nerves and muscles, causing muscle weakness and tiredness. Imaavy is used in patients whose immune system abnormally produces antibodies against acetylcholine receptors (AChR) or muscle-specific tyrosine kinase (MuSK), proteins found on muscle cells. It is used in addition to standard treatment for myasthenia gravis. Imaavy contains the active substance nipocalimab.
Therapeutic Indication
### Therapeutic indication Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Therapeutic Area (MeSH)
ATC Code
L04AL03
ATC Item
xl 04 al 03
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nipocalimab | N/A | Nipocalimab |
EMA Name
Imaavy
Medicine Name
Imaavy
Aliases
N/ANo risk management plan link.
